Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial

Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not...

Full description

Saved in:

Bibliographic Details
Published in:	Lancet neurology 2021-04, Vol.20 (4), p.275-283
Main Authors:	Walgaard, Christa, Lingsma, Hester F, Steyerberg, Ewout W, van den Berg, Bianca, Doets, Alexandra Y, Leonhard, Sonja E, Verboon, Christine, Huizinga, Ruth, Drenthen, Judith, Arends, Samuel, Budde, Ilona Kleine, Kleyweg, Ruud P, Kuitwaard, Krista, Samijn, Johnny P A, Vermeij, Frederique H, van Dijk, Gert W, Wirtz, Paul W, Eftimov, Filip, van der Kooi, Anneke J, Garssen, Marcel P J, Gijsbers, Cees J, de Rijk, Maarten C, Visser, Leo H, Blom, Roderik J, Linssen, Wim H J P, van der Kooi, Elly L, Verschuuren, Jan J G M, van Koningsveld, Rinske, Gilhuis, H Job, Jellema, Korné, van der Ree, Taco C, Bienfait, Henriette M E, Faber, Catharina G, Lovenich, Harry, van Engelen, Baziel G M, Groen, Rutger J, Merkies, Ingemar S J, van der Pol, W Ludo, van der Meulen, Willem D M, Badrising, Umesh A, Breukelman, Albert-Jan J, Zwetsloot, Casper P, van der Graaff, Maaike M, Wohlgemuth, Marielle, Hughes, Richard A C, Cornblath, David R, van Doorn, Pieter A, Jacobs, Bart C., Lingsma, Hester F., Steyerberg, Ewout W., Van den Berg, Bianca, Leonhard, Sonja E., Kleine Budde, Ilona, Van der Meulen, Marjon F.G., Vermeij, Frederique H., Kuks, Jan B.M., Van Dijk, Gert W., Garssen, Marcel P.J., Gijsbers, Cees J., Visser, Leo H., Blom, Roderik J., Linssen, Wim H.J.P., Van der Kooi, Elly L., Verschuuren, Jan J.G.M., Van Koningsveld, Rinske, Gilhuis, H. Job, Van der Ree, Taco C., Van Engelen, Baziel G.M., Groen, Rutger J., Merkies, Ingemar S.J., Van Oosten, Bob W., Van der Pol, W. Ludo, Van der Meulen, Willem D.M., Badrising, Umesh A., Breukelman, Albert-Jan J., Zwetsloot, Casper P., Bronner, I.M., Hoogendoorn, T.A., Van Houten, R., Krudde, J., Linn, F.H.H., Lion, J., Manschot, S.M., Mellema, S.J., Nieuwkamp, D.J., Oenema, D.G., Van Oostrom, J.C.H., Van Orshoven, N.P., Van der Ploeg, R.J.O., Polman, S., Ruitenberg, A., Ruts, L., Schyns-Soeterboek, A.J.G.M., Trip, R.
Format:	Article
Language:	eng
Subjects:	Adult Aged Analysis Clinical trials Double-Blind Method Double-blind studies Female Guillain-Barre syndrome Guillain-Barre Syndrome - drug therapy Humans Immunoglobulins Immunoglobulins, Intravenous - administration & dosage Immunomodulation Intravenous administration Male Medical prognosis Middle Aged Netherlands Patients Placebos Plasma Prognosis Thromboembolism Treatment Outcome Ventilators
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barré syndrome with a predicted poor outcome. In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (≥12 years) with Guillain-Barré syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of ≥6) according to the modified Erasmus Guillain-Barré syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7–9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barré syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. This study is registered with the Netherlands Trial Register, NTR 2224/NL2107. Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barré syndrome disability score at 4 weeks was 1·4 (95% CI 0·6–3·3; p=0·45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13–24 weeks after randomisation). Our study does not provide evidence that patients with Guillain-Barré syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other
ISSN:	1474-4422 1474-4465